medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 2

<< Back Next >>

Gac Med Mex 2017; 153 (2)

Case report: disseminated cutaneous leishmaniasis (LCD)

Mancheno-Valencia A, Cabezas-Arteaga J, Sacoto-Aizaga K, Arenas-Guzmán R

Language: Spanish
References: 29
Page: 251-254
PDF size: 129.60 Kb.


ABSTRACT

The World Health Organization (WHO) has classified leishmaniasis as an uncontrolled and emerging disease. In Ecuador, the only anecdotal cases of diffuse cutaneous leishmaniasis were recorded in 1994 and have not been formally published. This form can be differentiated from classical localized cutaneous leishmaniasis by the number of injuries, the clinical type of the main elementary lesions (papular and acneform), and a weak response to standard treatments. The case we report is a 34-year-old woman who presented with disseminated nodular lesions and ulcers of various sizes with erythematous edges and scars. We report the case and review diffuse cutaneous leishmaniasis and the differences that can be found with the other cutaneous variants. The diagnosis requires to be considered by primary care physicians in endemic areas and specialists, taking into account that this presentation can also occur in immunocompetent hosts.


REFERENCES

  1. WHO. Magnitude of the problem. World Health Organization. (Consultado el 21/7/2015.) Disponible en: http://www.who.int/leishmaniasis/burden/ magnitude/burden_magnitude/en/

  2. Calvopina M, Armijos RX, Hashiguchi Y. Epidemiology of leishmaniasis in Ecuador: current status of knowledge – a review. Mem Inst Oswaldo Cruz. Fundação Oswaldo Cruz; 2004;99:663-72.

  3. Couppie P, Clyti E, Sainte-Marie D, Dedet JP, Carme B, Pradinaud R. Disseminated cutaneous leishmaniasis due to Leishmania Guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558-60.

  4. Mondolfi AEP, Duffey GB, Horton LE, Tirado M, Jaimes OR, Perez-alvarez A, et al. Tropical medicine rounds intermediate/borderline disseminated cutaneous leishmaniasis. Int J Dermatol. 2013;52:446-55.

  5. Proyecto de vigilancia y control de vectores para prevención de la transmisión de enfermedades metaxénicas en el Ecuador. 2013- 2017. (Consultado el 20/7/2015.) Disponible en: instituciones.msp. gob.ec/dps/snem/images/proyectocontroldevectoresmetaxenicas.pdf

  6. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005;366:1561-77.

  7. Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A, Almeida RP, et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis. 2002;186:1829-34.

  8. Vieira-Gonçalves R, Pirmez C, Jorge ME, Souza WJS, Oliveira MP, Rutowitsch MS, et al. Clinical features of cutaneous and disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Paraty, Rio de Janeiro. Int J Dermatol. 2008;47:926-32.

  9. Guevara Ampudia MA. Prevalencia de leishmaniasis cutánea en el Cantón de Pedro Vicente Maldonado en el periodo de tiempo 2012 y 2013. Quito, 2013. (Consultado el 21/7/2013.) Disponible en: http://repositorio. usfq.edu.ec/handle/23000/2747

  10. Nery-Guimarães FV. Estado atual dos conhecimentos da “forma lepromatoide” da Leishmaniose tegumentar (LT). O Hospital.1965;67:71-91.

  11. Rincón MY, Silva SY, Dueñas RE, López-Jaramillo P. Leishmaniasis cutánea diseminada: reporte de dos casos en Santander, Colombia. Rev Salud Pública. 2009;11:145-50.

  12. Novais FO, Carvalho LP, Graff JW, Beiting DP, Ruthel G, Roos DS, et al. Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog. 2013;9:e1003504.

  13. Ordaz-Farias A, Muñoz-Garza FZ, Sevilla-González FK, Arana-Guajardo A, Ocampo-Candiani J, Treviño-Garza N, et al. Case report: transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana. Am J Trop Med Hyg. 2013;88:153-6.

  14. Gomes CM, Paula NA de, Morais OO de, Soares KA, Roselino AM, Sampaio RNR. Complementary exams in the diagnosis of American tegumentary leishmaniasis. An Bras Dermatol. 2014;89:701-9.

  15. Sinha S, Fernández G, Kapila R, Lambert WC, Schwartz RA. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol. 2008;47:1263-70.

  16. Verma GK, Verma S, Shanker V, Singh G, Tegta GR. A rare case of diffuse cutaneous leishmaniasis in an immunocompetent patient from sub-Himalayan India. Trop Doct. 2012;42:237-9.

  17. Montalvo AM, Fraga J, Monzote L, García M, Fonseca L. Diagnóstico de la leishmaniasis: de la observación microscópica del parásito a la detección del ADN. Rev Cubana Med Trop. 1999;64:108-31.

  18. Shirian S, Oryan A, Hatam G-R, Panahi S, Daneshbod Y. Comparison of conventional, molecular, and immunohistochemical methods in diagnosis of typical and atypical cutaneous leishmaniasis. Arch Pathol Lab Med. 2014;138:235-40.

  19. Ameen M. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Clin Exp Dermatol. 2010;35:699-705.

  20. Ministerio de Salud, Colombia, 2010. Guía de Atención Clínica Integral del Paciente con Leishmaniasis. Disponible en: https://www.minsalud. gov.co/Documents/.../Clinica%20Leishmaniasis.pdf

  21. Morrison B, Mendoza I, Delgado D, Reyes Jaimes O, Aranzazu N, Paniz Mondolfi AE. Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B: clinical dermatology concise report. Clin Exp Dermatol. 2010;35:116-20.

  22. Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat. 2001;12:159-62.

  23. Báfica A, Oliveira F, Freitas L a R, Nascimento EG, Barral A. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol. 2003;42:203-7.

  24. Eiras DP, Kirkman LA, Murray HW. Cutaneous leishmaniasis: current treatment practices in the USA for returning travelers. Curr Treat Options Infect Dis. 2015;7:52-62.

  25. Coelho AC, Trinconi CT, Costa CHN, Uliana SRB. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis. PLoS Negl Trop Dis. 2014;8:e2999.

  26. Ribeiro JBP, Miranda-Vilela AL, Graziani D, Gomes MR de A, Amorim AAS, Garcia RD, et al. Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice. Photodiagnosis Photodyn Ther. 2016;13:282-90.

  27. Turner KG, Vacchina P, Robles-Murguia M, Wadsworth M, McDowell MA, Morales MA. Fitness and phenotypic characterization of miltefosine-resistant Leishmania major. PLoS Negl Trop Dis. 2015;9:e0003948.

  28. Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines. 2003 Apr;2(2):239-52.

  29. Salaiza-Suazo N, Volkow P, Pérez Tamayo R, Moll H, Gillitzer R, Pérez- Torres A, et al. Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Trop Med Int Heal. 1999;4:801-11.




2020     |     www.medigraphic.com